Temporal characteristics of treatment-emergent adverse events and dose modifications with tivozanib and sorafenib in the phase 3 TIVO-3 study of relapsed or refractory mRCC.

Sumanta K. Pal,David F. McDermott,Bernard Escudier,Thomas E. Hutson,Camillo Porta,Elena Verzoni,Michael B. Atkins,Michael N. Needle,Brian I. Rini

Temporal characteristics of treatment-emergent adverse events and dose modifications with tivozanib and sorafenib in the phase 3 TIVO-3 study of relapsed or refractory mRCC.

2021

Sumanta K. Pal
David F. McDermott
Bernard Escudier
Thomas E. Hutson
Camillo Porta
Elena Verzoni
Michael B. Atkins
Michael N. Needle
Brian I. Rini

4567Background: The randomized phase 3 TIVO-3 study met the primary endpoint of improved PFS with tivozanib (TIVO) vs sorafenib (SOR) in patients with relapsed/refractory mRCC with fewer dose reduc...

Keywords:

in patient
Refractory
Internal medicine
Clinical endpoint
Oncology
Medicine
Adverse effect
Sorafenib
Tivozanib

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations